Adamas Pharmaceuticals Inc (NASDAQ:ADMS)’s share price gapped down prior to trading on Monday . The stock had previously closed at $7.52, but opened at $11.89. Adamas Pharmaceuticals shares last traded at $10.92, with a volume of 1535917 shares trading hands.
Several research firms have issued reports on ADMS. Leerink Swann reiterated an “outperform” rating on shares of Adamas Pharmaceuticals in a research note on Friday, October 19th. HC Wainwright set a $40.00 target price on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Monday. Mizuho lowered Adamas Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $75.00 to $18.00 in a research note on Monday. ValuEngine lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 28th. Finally, BidaskClub lowered Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $35.11.
The company has a market capitalization of $323.30 million, a price-to-earnings ratio of -2.77 and a beta of 1.53. The company has a quick ratio of 8.74, a current ratio of 8.95 and a debt-to-equity ratio of 1.01.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.34) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%. The business had revenue of $10.61 million for the quarter, compared to analyst estimates of $10.10 million. Analysts forecast that Adamas Pharmaceuticals Inc will post -5.37 earnings per share for the current fiscal year.
In other news, CFO Alfred G. Merriweather sold 1,665 shares of the business’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $19.18, for a total transaction of $31,934.70. Following the sale, the chief financial officer now owns 25,460 shares in the company, valued at $488,322.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 24.60% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new stake in shares of Adamas Pharmaceuticals during the second quarter worth about $130,000. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Adamas Pharmaceuticals by 43.2% during the second quarter. Metropolitan Life Insurance Co. NY now owns 7,606 shares of the specialty pharmaceutical company’s stock worth $196,000 after purchasing an additional 2,293 shares during the period. Sei Investments Co. lifted its holdings in shares of Adamas Pharmaceuticals by 49.8% during the first quarter. Sei Investments Co. now owns 7,627 shares of the specialty pharmaceutical company’s stock worth $182,000 after purchasing an additional 2,536 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in shares of Adamas Pharmaceuticals during the second quarter worth about $203,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Adamas Pharmaceuticals during the second quarter worth about $212,000. 95.65% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Adamas Pharmaceuticals (ADMS) Shares Gap Down to $11.89” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/11/05/adamas-pharmaceuticals-adms-shares-gap-down-to-11-89.html.
About Adamas Pharmaceuticals (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Featured Article: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.